IBEX:NASDAQIBEX Limited Analysis

IBEX is trading at $27.98, just above the calculated support of $25.94 and well below the 20‑day SMA of $27.88, indicating short‑term price pressure. The stock’s 20‑day, 50‑day and 200‑day moving averages are in a descending hierarchy (27.88 < 30.11 < 33.42) and the trend is flagged as bearish, while the MACD histogram has turned positive, offering a modest bullish signal. Valuation metrics are compelling: a trailing P/E of 9.3 versus an industry average of 33.7, a forward P/E of 7.6, and a discounted cash‑flow fair value of $59.14 suggest roughly 34% upside. Fundamentally, the company delivers strong returns with a 33.6% ROE, 12.4% ROA, 16.7% YoY revenue growth and improving EPS guidance (3.01 → 3.66).
Recent earnings commentary highlighted “among the strongest” quarterly results and management is emphasizing an AI‑driven “BPO 3.0” strategy, especially a pivot into health‑tech that could lift margins. Participation in the Sidoti Small‑Cap Virtual Conference adds visibility, and the strategic focus on AI‑powered customer engagement aligns with higher‑margin opportunities. Together, the deep valuation discount, solid cash‑flow generation and growth narrative support a longer‑term upside thesis despite near‑term bearish technical positioning.